AgomAb Therapeutics NVAGMB +0.85%14 Net Current Asset Value is $2.36 as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 55.1% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
AgomAb Therapeutics NV's net current asset value per share for the quarter that ended in Dec. 2025 was $2.36.
The historical rank and industry rank for AgomAb Therapeutics NV's Net Current Asset Value or its related term are showing as below:
AGMB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0 Med: 0 Max: 5.54
Current: 5.54
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of AgomAb Therapeutics NV was 5.54. The lowest was 0.00. And the median was 0.00.
AGMB's Price-to-Net-Current-Asset-Value is ranked worse than 55.1% of 942
companies
in the Biotechnology industry
Industry Median: 4.94
vs AGMB: 5.54
AgomAb Therapeutics NV (NAS:AGMB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
AgomAb Therapeutics NV Net Current Asset Value Related Terms
AgomAb Therapeutics NV Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for AgomAb Therapeutics NV's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV Net Current Asset Value Chart
AGMB vs DNA, ACRS, RLMD: Net Current Asset Value Comparison
For the Biotechnology subindustry, AgomAb Therapeutics NV's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.36 mean?
AgomAb Therapeutics NV (AGMB) has a Net Current Asset Value of $2.36 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #519 out of 942 companies in the Biotechnology industry, placing it in the top 55.1%.
Is AgomAb Therapeutics NV's Net Current Asset Value too high?
AgomAb Therapeutics NV's current Net Current Asset Value is $2.36. The Biotechnology industry median Net Current Asset Value is 4.94. AgomAb Therapeutics NV's value of $2.36 is 52.2% below this industry median. Based on the distribution chart, AgomAb Therapeutics NV ranks #519 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Net Current Asset Value compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #519 out of 942 companies for Net Current Asset Value. This places AgomAb Therapeutics NV in the lower half of its industry. The industry median Net Current Asset Value is 4.94. AgomAb Therapeutics NV's value of $2.36 is 52.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.94, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AgomAb Therapeutics NV's current Net Current Asset Value of $2.36 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current Net Current Asset Value is $2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Net Current Asset Value of $2.36. The current Net Current Asset Value is $2.36 and 52.2% below the Biotechnology industry median of 4.94. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Net Current Asset Value is $2.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 